版本:
中国

BRIEF-Veloxis Pharmaceuticals A/S, Endo Ventures enter deal to commercialize Envarsus XR in Canada

June 6 Veloxis Pharmaceuticals A/S :

* Veloxis Pharmaceuticals A/S and Endo Ventures Limited jointly announce agreement for Paladin Labs Inc. To commercialize Envarsus XR® in Canada

* Initial term of agreement is 15 years from effective date of agreement

* Under terms of deal, co will get up-front payment and veloxis will supply envarsus xr at a pre-specified transfer price​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐